Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 16

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Epileptic encephalopathy

Recruiting

Study on the Safety and Effectiveness of Bexicaserin for Seizures in Children and Adults with Developmental and Epileptic Encephalopathy

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Longboard Pharmaceuticals Inc.

Cerebrovascular accident

Recruiting

Study on the Safety and Effectiveness of Sovateltide for Patients with Acute Ischemic Stroke

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SOVATELTIDE
  • Sponsor:Pharmazz EU Limited

Diabetic foot+1

Recruiting

Study on the Effect of Semaglutide on Healing Foot Ulcers in Patients with Type 2 Diabetes

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Region Hovedstaden

Dementia Alzheimer's type

Recruiting

Study on Brain Imaging for Alzheimer's Disease Using Florquinitau (18F) in Patients with Mild Cognitive Impairment and Early Alzheimer's Symptoms

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Florquinitau (18F)
  • Sponsor:Cliniques Universitaires Saint-Luc

Trisomy 21+1

Recruiting

Study on the Use of 18F-PI-2620 to Detect Alzheimer's in People with Down Syndrome

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Izaflortaucipir (18F)
  • Sponsor:Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Cognitive disorder

Recruiting

Comparison of Three PET Tau Tracers ([18F]RO948, [18F]PI2620, and [18F]MK-6240) in People with Cognitive Impairment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · Healthy volunteers
  • Substances:Florquinitau (18F)
  • Sponsor:Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Progressive supranuclear palsy+1

Recruiting

Study on the Use of 18F-PI-2620 for Patients with Progressive Supranuclear Palsy and Parkinson's Disease

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Izaflortaucipir (18F)
  • Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’investigacions Biomediques August Pi I Sunyer

Glioblastoma multiforme

Recruiting

Study on How Bevacizumab Affects the Immune System in Patients with Glioblastoma Multiforme

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Bevacizumab
  • Sponsor:Orszagos Onkologiai Intezet

Dementia+7

Recruiting

Study on the Accuracy of Tau PET ([18F]RO6958948) and Vizamyl (Flutemetamol 18F) in Diagnosing Mild Cognitive Symptoms and Risk of Alzheimer's Disease

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Flutemetamol (18F)
  • Sponsor:Region Skane

Frontotemporal dementia

Recruiting

Study on the Safety and Effects of DNL593 for Patients with Frontotemporal Dementia

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:DNL593
  • Sponsor:Denali Therapeutics Inc.

Dementia Alzheimer's type

Recruiting

Study on Brain Changes in Alzheimer's Disease Using Flutemetamol (18F) and Fludeoxyglucose (18F) in ALFA Project Participants

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Flutemetamol (18F)
  • Sponsor:Barcelonabeta Brain Research Center

Transient ischaemic attack+1

Recruiting

Study on Metabolic Impairment in ALS and TIA Patients Using Hyperpolarized Pyruvate MRI

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Pyruvic Acid
  • Sponsor:Aarhus University

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.